Intellia Therapeutics
Intellia presents CRISPR gene-editing science, clinical programs, and scientific publications on its official website. Its gene-editing work belongs in this broader in vivo engineering field; it should not be labeled as equivalent to in vivo CAR-T.
Corporate information
- Company entity
- Intellia Therapeutics
- Headquarters / principal office
- Cambridge, MassachusettsSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2014 ↗
- Ownership / capital status
- Publicly tradedNasdaq-listed; NTLA ↗
- Official corporate reference
- https://www.intelliatx.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Intellia presents CRISPR gene-editing science, clinical programs, and scientific publications on its official website. Its gene-editing work belongs in this broader in vivo engineering field; it should not be labeled as equivalent to in vivo CAR-T.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Intellia Therapeutics — official company page
- Intellia 2021 Form 10-K — incorporated May 2014
- Company-managed LinkedIn profile — self-reported location